Clinical study on the treatment of post-stroke cognitive impairment nondementia in kidney essence deficiency patients with Dihuang Yizhi formula.

Objective We aimed to observe the efficacy of Dihuang Yizhi formula in post-stroke cognitive impairment non-dementia(PSCIND) in kidney essence deficiency patients. Methods A total of 116 patients with PSCIND admitted to Longhua hospital between July 2019 and January 2021 were randomized into the experimental group(n =58) and the control group(n = 58). In the experimental group, Dihuang Yizhi formula was used; in the control group, piracetam tablets were used for a course of 6 months. All patients were assessed with the Mini-Mental State Examination(MMSE), the Montreal Cognitive Assessment( MoCA) scale, the Zarit Burden Inventory(ZBI), the Ability to perform Daily Living(ADL) scale, and the traditional Chinese medicine(TCM) syndrome score before, at 3 months, and at 6 months of treatment. Results During the treatment, five cases fell off in the experimental group and four cases in the control group. Finally, 53 cases in the experimental group and 54 cases in the control group completed this study. Compared with before treatment, patients in both groups had elevated MMSE and MoCA scores after 6 months of treatment(P<0. 05), with the increase in MMSE and MoCA scores being correlated with time(P <0. 01). The ZBI scores of the patients in the experimental group decreased after 3 months of treatment(P<0. 01), and after 6 months of treatment, only the ZBI scores of the patients in the experimental group decreased(P<0. 01). The decrease in ZBI was associated with time and group x time interactions(P<0. 01). In the MoCA sub-items, after 6 months of treatment, increases in scores of naming( P<0. 05), memory and calculation(P<0. 01), and language and abstraction(P<0. 01) were related to time, whereas increases in scores of delayed recall were related to group x time interactions(P< 0. 01). After 6 months of treatment, ADL scores decreased in the experimental group(P<0. 01), and the decrease in ADL scores was associated with time(P<0. 01) and group x time interactions(P<0. 05). After 3 months of treatment, the TCM syndrome scores of patients in the experimental group decreased(P< 0. 01), while after 6 months of treatment, the TCM syndrome scores of patients in both groups decreased (P<0. 01). The decrease in TCM syndrome scores was correlated with time and group x time interactions (P<0. 01). Safety indicators were normal in all patients before and after treatment. Conclusion Based on the theory of "tonifying the kidney and supplementing the essence," Dihuang Yizhi formula can improve the cognitive function of PSCIND patients, improve their quality of life, and reduce the burden on their families, exhibiting certain advantages over piracetam. [ABSTRACT FROM AUTHOR]